The Short Answer
Aspirin (81 mg daily, $4–8/month) is first-line for primary thrombocytosis without prior clots. Hydroxyurea (500–1,000 mg daily, $30–60/month) is used for high-risk patients or those who don't respond to aspirin. Secondary thrombocytosis rarely needs antiplatelet therapy; treating the underlying cause (iron, infection) usually works [1][7][8].
Aspirin works by making platelets less sticky. Low-dose aspirin (81 mg daily) reduces clot risk in primary thrombocytosis by about 30–40% without major bleeding risk. It's cheap, well-tolerated, and available over-the-counter. Federal trials show aspirin is safe long-term in thrombocytosis patients. Cost: $4–8 per month generic [1][7].
Hydroxyurea is a chemotherapy drug that slows bone marrow platelet production. It lowers platelet count to <400,000 in 80–90% of patients within 2–4 weeks. It's used for high-risk primary thrombocytosis (age >60, prior clot, or platelet >600,000). Side effects include nausea, low blood counts, and rare skin cancer risk with long-term use. Cost: $30–60 per month generic [7][8].
For secondary thrombocytosis, the real treatment is fixing the cause. Iron supplementation (ferrous sulfate 325 mg daily, $8–15/month) brings platelets down in iron-deficiency thrombocytosis. Treating infection or cancer resolves thrombocytosis in most secondary cases. Platelet apheresis (mechanical removal) is reserved for emergencies (platelet >1,000,000 with bleeding or clots). Cost: $2,000–5,000 per apheresis session [1][4][9].
Try This Today
Ask your doctor: 'Do I need aspirin, hydroxyurea, or just monitoring?' If you're on hydroxyurea, get CBC and liver/kidney tests every 1–3 months. If you're on aspirin alone, annual monitoring is usually enough. This prevents expensive ER visits from missed side effects.